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Amelioration of Cognitive Impairment in the Type-2
Diabetic Mouse by the Angiotensin II Type-1 Receptor
Blocker Candesartan
Kana Tsukuda, Masaki Mogi, Jian-Mei Li, Jun Iwanami, Li-Juan Min, Akiko Sakata, Teppei Fujita,
Masaru Iwai, Masatsugu Horiuchi
Abstract—Angiotensin II type-1 receptor blockers are widely used with the expectation of prevention of stroke,
potential effects to ameliorate of type-2 diabetes, which seems to be closely associated with the impairment of
cognitive function in humans. Recently, we have reported that an angiotensin II type-1 receptor blocker prevented
cognitive impairment in mice after focal cerebral ischemia, at least partly through an angiotensin II type-2
receptor-mediated increase in a neuroprotective factor, methyl methanesulfonate sensitive-2. Here, we examined
the possibility that an angiotensin II type-1 receptor blocker could improve cognitive function in a type-2 diabetic
mouse model, KK-Ay. KK-Ay mice subjected to 20 trials of a passive avoidance task every week from 8 weeks
exhibited a significantly impaired avoidance rate, and moreover, its age-dependent decline, especially after 14
weeks of age, compared with age-matched C57BL6 mice. Oral administration of candesartan at a nonhypotensive
dose (0.005% in laboratory chow) in KK-Ay mice improved cognitive function and inhibited the impairment of
cognitive decline. Methyl methanesulfonate sensitive-2 expression in the brain was lower in KK-Ay mice than in
C57BL6 mice. Treatment with candesartan markedly increased mRNA expression of angiotensin II type-2 receptor
and methyl methanesulfonate sensitive-2 in the brain in KK-Ay mice, determined by quantitative RT-PCR. In
KK-Ay mice treated with candesartan, age-dependent increases in blood glucose and insulin were significantly
suppressed. Our results suggest that candesartan ameliorates the impaired cognitive function in type-2 diabetes
mice, at least because of an increased expression of methyl methanesulfonate sensitive-2, a neuroprotective factor,
in addition to improvement of glucose intolerance. (Hypertension. 2007;50:1099-1105.)
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Type 2 diabetes mellitus (T2DM) and hypertension havebeen highlighted as risk factors for cognitive decline in
several clinical studies.1–3 The increased risk of dementia
associated with T2DM relates to both Alzheimer disease and
vascular dementia.4 Recently, Yaffe et al2 reported that
diabetic, as well as prediabetic, women have impaired cog-
nitive function and a greater risk of developing cognitive
impairment. Moreover, an emerging body of evidence sug-
gests that an increased prevalence of insulin abnormalities
and insulin resistance in Alzheimer disease may contribute to
the disease pathophysiology and clinical symptoms.5 Hyper-
insulinemia observed in patients with impaired glucose tol-
erance (IGT) has also been focused on as an important risk
factor for diminished cognition,6,7 indicating that patients
with T2DM or IGT would be highly exposed to the possibil-
ity of impaired cognitive performance. There is concern that
the number of individuals diagnosed with T2DM are esti-
mated to increase to 220 million by 2010,8 and the number of
people with undiagnosed diabetes or IGT will increase much
more, suggesting that T2DM- or IGT-induced cognitive
decline will become a major worldwide clinical problem in
the future. However, the detailed mechanism and therapeutic
approach for cognitive impairment associated with T2DM or
glucose intolerance, especially using a mouse model, have
never been investigated.
Recent major clinical research, such as the Heart Outcomes
Prevention Evaluation,9 Losartan Intervention for Endpoint
Reduction,10 Acute Candesartan Cilexetil Therapy in Stroke
Survivors,11 Morbidity and Mortality After Stroke,12 and Jikei
Heart Study,13 indicates that blockade of the renin-angioten-
sin system, especially by an angiotensin II type-1 receptor
blocker (ARB), is effective to prevent a first or recurrent
stroke or consequent cardiovascular events. ARBs are also
widely used with the expectation of potential amelioration of
the metabolic syndrome, which is defined as a cluster of
obesity, high blood pressure, increase in glucose level includ-
ing IGT, and dyslipidemia and appears to increase the
incidence of cardiovascular diseases and stroke. Recently,
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large clinical trials indicate that new onset of diabetes would
be prevented by ARB14,15 probably by an improvement of
insulin sensitivity and glucose metabolism, although the
detailed mechanisms are still waiting to be elucidated. We
reported previously that an ARB increased insulin sensitivity
with a decrease in plasma glucose concentration via an
increase in insulin-mediated glucose transporter translocation
to the plasma membrane in a T2DM mouse model, KK-Ay,16
indicating that ARB may have dual effects of brain protection
and amelioration of the metabolic syndrome.
Recently, we have also reported that an ARB prevented
cognitive impairment in mice after focal cerebral ischemia at
least partly, with an angiotensin II type-2 (AT2) receptor-
mediated increase in a neuroprotective factor, methyl meth-
anesulfonate sensitive 2 (MMS2), which is one of the
ubiquitin-conjugating enzyme variants,17 indicating that treat-
ment with an ARB could be therapeutically effective to
prevent cognitive decline in T2DM patients. However, the
effect of ARB on cognitive function in patients with T2DM is
not well known. Here, we examined the possibility that an
ARB could improve cognitive function in genetic T2DM
model mice, KK-Ay.
Methods
This study was performed in accordance with the National Institutes
of Health guidelines for the use of experimental animals. All of the
animal studies were reviewed and approved by the animal studies
committee of Ehime University.
Animals and Treatment
Adult male KK-Ay mice and C57BL6 mice (CLEA, Tokyo, Japan)
were used in this study. Mice were fed a powdered diet (Oriental
Yeast Co Ltd) with or without a selective ARB, candesartan
(provided by Takeda Pharmaceutical Co Ltd), and water at libitum.
We chose 2 different doses of candesartan (0.001% or 0.005% in
laboratory chow) in terms of glucose metabolism as reported
previously.18 We performed 2 types of experiments as follows. In a
short-term experiment, mice were treated with candesartan for 5
weeks from 15 weeks of age, at which point KK-Ay mice showed a
marked cognitive decline. In a long-term experiment, the mice were
treated with candesartan for 7 weeks from 8 weeks of age. Plasma
cholesterol level was measured by the cholesterol oxidase method
(Cholesterol E-test, WAKO Chemical Industries, Ltd), and blood
glucose level was measured by the glucose oxidase method (Glucose
CII-test, WAKO Chemical Industries, Ltd). Insulin level was mea-
sured by ELISA (Ultra Sensitive Rat Insulin kit, Morinaga Institute
of Biological Science, Inc).
Figure 1. KK-Ay mice exhibited significant impairment of cogni-
tive function after stroke. Passive avoidance tasks were per-
formed weekly from 6 weeks old. Mice were given 20 inescap-
able scrambled shocks. Candesartan was administered from 8
weeks old (0.001% or 0.005% in laboratory chow) or 15 weeks
old (0.005% in laboratory chow). A, Comparison of avoidance
rate between C57BL6 and KK-Ay mice. , C57BL6 mice; f,
KK-Ay mice. *P0.05 vs C57BL6 mice. n10 for each group.
Comparison with the ratio of avoidance rate to that of 7 weeks
of age in KK-Ay mice without candesartan treatment (depicted
as 1). B, Improvement of avoidance rate by treatment with can-
desartan from 8 weeks old. , C57BL6 mice; f, KK-Ay mice;
‚, KK-Ay mice with candesartan (0.001% in laboratory chow);
E, KK-Ay mice with candesartan (0.005% in laboratory chow).
*P0.05 vs KK-Ay mice without candesartan. n7 to 10 for
each group. Comparison with the ratio of avoidance rate to that
of 7 weeks of age in KK-Ay mice without candesartan treatment
(depicted as 1). C, Beneficial inhibitory effect of treatment with
candesartan from 15 weeks old on impairment of avoidance
rate. f, KK-Ay mice; E, KK-Ay mice with candesartan (0.005% in
laboratory chow). *P0.05 vs KK-Ay mice without candesartan.
Figure 1 (Continued). n5 for each group. Comparison with
the ratio of avoidance rate to that of 9 weeks of age in KK-Ay
mice without candesartan treatment (depicted as 1).
Table 1. Blood Pressure in KK-Ay Mice After 7 Weeks of
Treatment With or Without Candesartan From 8 Weeks of Age
Groups Systolic Blood Pressure, mm Hg
C57BL6 90.72.0
KK-Ay 94.55.0
KK-Ay Cand-1 89.43.6
KK-Ay Cand-5 85.64.8
Cand-1 indicates candesartan (0.001%); Cand-5, candesartan (0.005%). No
significant change was observed among these groups.
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Blood Pressure Measurement
Systolic blood pressure was monitored in conscious mice by the
tail-cuff method (MK-1030, Muromachi Co Ltd) twice before
candesartan treatment and at the “end” of each experiment, as
described in a previous report.19 Mice were held in a small plastic
holder on a warming pad that was thermostatically controlled at
37°C. Mean systolic blood pressure of 10 measurements in each
group was determined.
Passive Avoidance Test
A passive avoidance test was performed as described previously.17
Briefly, a shuttle avoidance cage (3212.515 cm; Melquest) and
an isolation cabinet (484237 cm; Melquest) were used. The
shuttle avoidance box was divided into equal-size chambers by a
stainless-steel divider. Scrambled shocks were delivered by a shock
generator (SG-200, Melquest). Mice were individually placed in a
chamber and given 20 inescapable electric shocks (0.3 mA) of 3
seconds’ duration, at intervals of 2 seconds. A tone signal was presented
during the first 5 seconds of each trial. If there was no avoidance
response within this period, the tone signal remained on, and a shock
was delivered through the grid floor. In the case of no escape response
within this period, both the tone and shock were automatically termi-
nated. The number of escape failures, which was defined as a noncross-
ing response during shock delivery, was recorded.
Real-Time RT-PCR Method
Real-time quantitative RT-PCR was performed with a SYBR green
I kit (MJ Research, Inc). PCR primers were shown in Table S1
(available online at http://hyper.ahajournals.org).
Statistical Analysis
All of the data are expressed as meanSE in the text and figure. Data
were analyzed by 2-way ANOVA. When a statistically significant
effect was found, posthoc analysis was performed to detect the
difference between the groups. A value of P0.05 was considered to
be statistically significant.
Results
Candesartan Improved Cognitive Function and
Inhibited Cognitive Decline in KK-Ay Mice
KK-Ay mice exhibited significant failure of improvement in
the avoidance rate and its time-dependent decline after 14
weeks of age compared with age-matched C57BL6 mice
(Figure 1A). To examine the possibilities that candesartan
could prevent and/or improve cognitive decline, we admin-
istered candesartan in 2 different ways, from 8 weeks of age
and from 15 weeks of age. In KK-Ay mice, administration of
a higher dose of candesartan (0.005% in laboratory chow)
from 8 weeks of age markedly improved cognitive function to
a level similar to that in age-matched C57BL6 mice, and
administration of a lower dose of candesartan (0.001% in
laboratory chow) from 8 weeks of age also significantly restored
cognitive function (Figure 1B). Blood pressure was not signifi-
cantly changed in mice treated with candesartan from 8 weeks of
age (Table 1). KK-Ay mice showed severe cognitive decline at
15 weeks of age, and administration of candesartan (0.005% in
laboratory chow) starting from 15 weeks of age inhibited this
cognitive decline (Figure 1C), with no apparent change in blood
pressure (Table 2). Body weight was higher in KK-Ay mice, and
brain:body weight ratio was lower in KK-Ay mice at 21 weeks
of age (Figure 2), with no apparent difference in brain weight
between the 2 groups. Administration of candesartan (0.005% in
laboratory chow) did not influence body weight or the brain-
:body weight ratio (Figure 2).
Treatment With Candesartan Increased MMS2
Expression in KK-Ay Mice
Next, we assessed the effect of candesartan on mRNA expres-
sion determined by quantitative RT-PCR in the brain of mice
with or without administration of candesartan (0.005% in labo-
ratory chow) starting from 15 weeks of age. Brain samples were
obtained from 21-week-old mice at the end of the experiment in
the late treatment group. In KK-Ay mice, mRNA expression of
the AT2 receptor and MMS2 in the brain was lower compared
with that in C57BL6 mice (Figure 3). Treatment with candesar-
tan markedly increased mRNA expression of the AT2 receptor
(Figure 3A) and MMS2 (Figure 3B) in the brain of KK-Ay mice.
On the other hand, mRNA expression of the angiotensin II
type-1 receptor in the brain was not significantly different
between each group (data not shown).
Effect of Candesartan on Plasma Glucose and
Insulin Concentrations in KK-Ay Mice
In KK-Ay mice, age-dependent increases in blood glucose
and insulin levels were observed compared with C57BL6
mice. Blood samples were obtained from 21-week-old
mice in the late-treatment group. Treatment with cande-
Table 2. Blood Pressure in KK-Ay Mice After 5 Weeks of
Treatment With or Without Candesartan From 15 Weeks of Age
Groups Systolic Blood Pressure, mm Hg
C57BL6 96.81.1
KK-Ay 97.86.7
KK-Ay with Cand 93.74.5
Cand indicates candesartan (0.005%). No significant change was observed
among these groups.
Figure 2. Comparison of body weight (A) and
brain:body weight ratio (B) between C57BL6
mice and KK-Ay mice (21 weeks old) treated
with or without candesartan (0.005% in labora-
tory chow). *P0.05 vs C57BL6 mice. n5 to 6
for each group.
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sartan significantly suppressed such an increase in serum
glucose and insulin (Figure 4A and 4B). We reported
recently that treatment with candesartan suppressed the
increase in the plasma glucose level in the oral glucose
tolerance test without a significant change in the insulin
concentration and glucose uptake, determined by 2-[3H]
deoxyglucose uptake, in 10-week-old mice treated with
candesartan for 2 weeks, an significantly increased in the
brain of KK-Ay mice and in adipose tissues, skeletal
muscle, and heart,18 indicating that treatment with cande-
sartan improved the insulin resistance. Interestingly,
KK-Ay mice treated with candesartan showed a significant
reduction of serum cholesterol level (Figure 4C).
Effect of Candesartan on NADPH Oxidase
Subunits in KK-Ay Mice
Next, we assessed the involvement of oxidative stress in the
cognitive decline in KK-Ay mice. We measured mRNA levels
of reduced nicotinamide-adenine dinucleotide phosphate ox-
idase subunits, p47phox and Rac-1, in the brain by quantitative
RT-PCR. In KK-Ay mice, mRNA expressions of p47phox and
Rac-1 have a tendency to increase compared with C57BL6
mice; however, no significant changes of these expressions
were observed with candesartan treatment in KK-Ay mice
(Figure 5A and 5B).
Discussion
Our results demonstrated that cognitive function declined
age dependently in T2DM mice, KK-Ay, and administra-
tion of candesartan ameliorated the impaired cognitive
function in T2DM mice, with no change in blood pressure,
partly because of multitherapeutic efficacy, such as an
improvement of glucose intolerance and an increase in the
expression of a neural differentiation gene, MMS2. Meta-
bolic syndrome–induced cognitive impairment has re-
cently received attention. In particular, T2DM-induced
cognitive decline has been widely recognized clinically.
However, its mechanism is complicated and not well
understood. Several mechanisms have been considered,
such as the effects of prolonged hyperglycemia, hyperin-
sulinemia, associated hypertension, and cerebrovascular
disease. Early findings suggest some beneficial effect on
cognition to be gained through improving glycemic con-
trol, and the potential for preventing a downward spiral of
cognitive impairment, decreased medication compliance,
and worsening control should always be considered. Insu-
lin resistance is a potentially modifiable midlife risk factor
for cognitive decline and dementia.20 Moreover, diabetes
mellitus is associated with decreased cognitive function
and greater cognitive decline, especially in women,2,21
indicating that improvement of glucose metabolism could
prevent cognitive decline. Microcirculation disorders and
endothelial dysfunction are thought to be involved in
cognitive impairment in T2DM patients. Treatment with
candesartan is reported to improve tonic NO release and
resulted in inhibition of endothelial dysfunction.22 More-
over, treatment with candesartan decreased cerebral vas-
cular inflammation,23 decreased the macrophage infiltra-
tion, and increased inflammatory cytokines24 in the
spontaneously hypertensive rat. Oxidative stress is well
known to induce brain aging and neurodegenerative dis-
ease.25 An increase in advanced glycation end-product
formation and aldose reductase-polyol pathway flux is
reported to be among the main mechanisms induced by
oxidative stress and involved in end-organ damage in
diabetes mellitus.26,27 However, we found no significant
difference in the expressions of reduced nicotinamide-
adenine dinucleotide phosphate oxidase subunits in the
brain between C57BL6 and KK-Ay mice, and candesartan
did not affect these expressions, indicating that prevention
of oxidative stress does not apparently play a major role in
improving of cognitive decline in KK-Ay mice by cande-
sartan. However, more detailed analysis of oxidative
stress, such as superoxide anion production, reduced
nicotinamide-adenine dinucleotide phosphate oxidase ac-
tivities, and scavenging system, etc, are necessary for
further discussion.
Figure 3. Effect of candesartan on AT2 receptor and MMS2
mRNA expression determined by the real-time PCR method.
Comparison of AT2 receptor (A) and MMS2 (B) between C57BL6
mice and KK-Ay mice (21 weeks old) treated with or without
candesartan (0.005% in laboratory chow). *P0.05 vs C57BL6
mice. n5 to 6 for each group.
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Our findings also showed a reduction of serum cholesterol
level in KK-Ay mice treated with candesartan. Hypercholes-
terolemia was independently correlated with memory dys-
function in a stroke-free cohort.28 An ARB, olmesartan, has
been reported to reduce the plasma cholesterol level in
angiotensin II–infused, fructose-rich, chow-fed rats.29 On the
other hand, an AT2 receptor agonist, CGP42112A, signifi-
cantly reduced total cholesterol and non–high-density li-
poprotein cholesterol in similarly treated rats,29 indicating
that angiotensin II receptor signaling partly works as a
determinant of cholesterol levels. Moreover, many reports
support that blockade of the renin-angiotensin system im-
proves the metabolic syndrome.30 We reported that treatment
with candesartan increased the expression of adiponectin and
decreased tumor necrosis factor- expression in adipose
tissue in KK-Ay mice.18 Similarly, it has been reported that
candesartan treatment decreased serum leptin levels and
tumor necrosis factor- mRNA expression and increased
serum adiponectin levels in Wistar Kyoto rats.31 In contrast,
Erbe et al32 demonstrated that oral administration of cande-
sartan for 4 days did not affect either glucose or insulin levels
in ob/ob mice; however, this apparent discrepancy could be
mainly because of the duration of candesartan treatment and
probably because of the differences in mouse models. These
results indicate that candesartan could improve lipid metab-
olism and adipocyte differentiation and result in improvement
of cognitive function in KK-Ay mice.
Recently, we reported the contribution of AT2 receptor
signaling to neural differentiation, with upregulation of
MMS2.17 MMS2 is one of the ubiquitin-conjugating enzyme
variants and is related to neural differentiation33 and DNA
repair.34 MMS2 promotes error-free bypass in the RAD6
pathway of DNA damage tolerance.35 In patients with T2DM,
urinary 8-hydroxy-2-deoxyguanosine, a sensitive biomarker
of oxidative DNA damage, has been reported to be in-
creased.36 Our recent report demonstrated that MMS2 expres-
sion is increased in pathological conditions such as stroke and
that knocking down of the MMS2 gene using small-
interference RNA in vivo enhanced the decline in cognitive
function after brain damage,17 indicating that MMS2 plays a
pivotal role in cognition under critical conditions. The MMS2
mRNA level was increased by candesartan treatment in the
brain of KK-Ay mice. Therefore, upregulation of MMS2 may
protect diabetes-associated brain damage with preventive
effects on DNA damage. We speculate on the possibility that
AT2 receptor–induced MMS2 upregulation may contribute to
the improvement of cognitive function in KK-Ay mice.
However, the exact localizations of the AT2 receptor and
Figure 4. Effect of candesartan on serum
glucose, insulin, and total cholesterol
levels. Comparison of serum levels of
glucose (A), insulin (B), and total choles-
terol (C) between C57BL6 mice and
KK-Ay mice (21 weeks old) treated with
or without candesartan (0.005% in labo-
ratory chow). *P0.05 vs C57BL6 mice.
n5 to 6 for each group.
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MMS2 have to be elucidated in KK-Ay mice, and the effects
of AT2 receptor stimulation in the brain in KK-Ay mice on
insulin sensitivity have to be elucidated. Therefore, it is still
immature to conclude that an increase in the AT2 receptor in
KK-Ay mouse brain could contribute to the improvement of
cognitive function by candesartan. In the future, more de-
tailed studies are necessary to discuss the roles of AT2
receptor stimulation in cognition in diabetes.
We could not observe the significant change in blood
pressure measured by the tail-cuff method between KK-Ay
mice with or without candesartan. However, 10% reduc-
tion in blood pressure was observed in 0.005% of
candesartan-treated KK-Ay mice. Therefore, it is possible
that this reduction of blood pressure in our experiments
could contribute to the inhibitory effect of candesartan on
cognitive impairment in diabetic mice. Moreover, clini-
cally, poor blood pressure control may affect cognitive
function in patients with diabetes. This animal model did
not show hypertension during the experiment. Therefore,
this study design using KK-Ay mice is different from
clinical cases and includes experimental limitation. More-
over, KK-Ay mice show obesity. Therefore, more clinically
relevant experiments to assess the clinical importance of
our observation related more to T2DM-associated cogni-
tive decline need to be designed in the future.
Clinically, recent the large clinical trial in the Jikei Heart
Study demonstrated that the addition of the ARB valsartan
reduced 40% in stroke onset compared with supplementary
conventional treatment without ARB independent of blood
pressure reduction.13 Furthermore, a double-blind clinical
trial37 proved that an ARB, losartan, has an additional
therapeutic effect on impaired cognitive function beyond its
antihypertensive effect, compared with another antihyperten-
sive drug, hydrochlorothiazide, indicating a contribution of
ARB to brain protection involving the prevention of cognitive
impairment. The present study demonstrated T2DM-
associated cognitive impairment and an inhibitory effect of an
ARB on this disorder using a mouse model. Further clinical
investigations are necessary to confirm this beneficial effect
of candesartan in the future.
Perspectives
Our results demonstrated that candesartan ameliorates the
impaired cognitive function induced by T2DM, with multiple
beneficial effects. Hundreds of millions of people would be
faced with T2DM in the future. Moreover, cognitive decline
associated with T2DM would impair the quality of life in
patients with T2DM, indicating that a preventive approach for
T2DM-induced cognitive impairment will be the worldwide
critical issue. Therefore, an interventional approach by ARB
is expected to contribute to the inhibition of T2DM-
associated cognitive impairment and to improve the quality of
life for elderly persons.
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